永井 崇敬 (ナガイ タカヒロ)

NAGAI Takahiro

写真a

所属

医学部 医学科 発達泌尿生殖医学講座泌尿器科学分野

職名

助教

外部リンク

 

論文 【 表示 / 非表示

  • A case of primary aldosteronism with excessive secretion of renin that was unmasked by kidney transplantation. 査読あり

    Fujimoto K, Hisanaga S, Kuroda S, Kodama K, Sugiyama F, Kikuchi M, Kita T, Yamashita A, Nagai T, Kamimura T, Kaikita K, Imamura T, Fujimoto S

    CEN case reports   2023年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1007/s13730-023-00784-9

    PubMed

  • Identification of the α2 chain of interleukin-13 receptor as a potential biomarker for predicting castration resistance of prostate cancer using patient-derived xenograft models 査読あり

    Nagai T., Terada N., Fujii M., Nagata Y., Nakahara K., Mukai S., Okasho K., Kamiyama Y., Akamatsu S., Kobayashi T., Iida K., Denawa M., Hagiwara M., Inoue T., Ogawa O., Kamoto T.

    Cancer Reports   6 ( 2 )   2023年2月

     詳細を見る

    掲載種別:研究論文(学術雑誌)   出版者・発行元:Cancer Reports  

    Background: Several treatment strategies use upfront chemotherapy or androgen receptor axis-targeting therapies for metastatic prostate cancer. However, there are no useful biomarkers for selecting appropriate patients who urgently require these treatments. Methods: Novel patient-derived xenograft (PDX) castration-sensitive and -resistant models were established and gene expression patterns were comprehensively compared. The function of a gene highly expressed in the castration-resistant models was evaluated by its overexpression in LNCaP prostate cancer cells. Protein expression in the tumors and serum of patients was examined by immunohistochemistry and ELISA, and correlations with castration resistance were analyzed. Results: Expression of the α2 chain of interleukin-13 receptor (IL13Rα2) was higher in castration-resistant PDX tumors. LNCaP cells overexpressing IL13Rα2 acquired castration resistance in vitro and in vivo. In tissue samples, IL13Rα2 expression levels were significantly associated with castration-resistant progression (p < 0.05). In serum samples, IL13Rα2 levels could be measured in 5 of 28 (18%) castration-resistant prostate cancer patients. Conclusion: IL13Rα2 was highly expressed in castration-resistant prostate cancer PDX models and was associated with the castration resistance of prostate cancer cells. It might be a potential tissue and serum biomarker for predicting castration resistance in prostate cancer patients.

    DOI: 10.1002/cnr2.1701

    Scopus

  • Epithelioid Angiomyolipoma with Tumor Thrombus into Inferior Vena Cava Presurgically Treated with Combination Therapy of Pembrolizumab and Axitinib: A Case Report 査読あり

    Kawasoe C., Miyamoto Y., Ito K., Murashima T., Nagai T., Takamori H., Kiwaki T., Kamimura T., Mukai S., Kamoto T.

    Research and Reports in Urology   15   447 - 452   2023年

     詳細を見る

    掲載種別:研究論文(学術雑誌)   出版者・発行元:Research and Reports in Urology  

    Epithelioid angiomyolipoma (EAML) is a rare variant of AML with malignant potential. It is occasionally difficult to distinguish EAML from renal cell carcinoma (RCC) on imaging. A 72-year-old woman was admitted to our hospital for the treatment of a left renal tumor with relatively high blood flow and a tumor thrombus extending to the inferior vena cava, suggesting RCC. The patient underwent presurgical combination therapy with axitinib and pembrolizumab. This treatment significantly shortened the thrombus, and radical nephrectomy was performed. The pathological findings were compatible with EAML, and the treatment effects were observed. We report a case treated pre-surgically with a combined therapy of pembrolizumab and axitinib, with a favorable response as a treatment option for EAML.

    DOI: 10.2147/RRU.S425887

    Scopus

  • Identification of the α2 chain of interleukin-13 receptor as a potential biomarker for predicting castration resistance of prostate cancer using patient-derived xenograft models 査読あり

    永井 崇敬

    Cancer reports   2022年8月

     詳細を見る

    担当区分:筆頭著者   掲載種別:学位論文(博士)  

  • Pleiotropic effects of probenecid on three-dimensional cultures of prostate cancer cells 査読あり

    Uwada J., Mukai S., Terada N., Nakazawa H., Islam M.S., Nagai T., Fujii M., Yamasaki K., Taniguchi T., Kamoto T., Yazawa T.

    Life Sciences   278   119554   2021年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Life Sciences  

    Aims: Chemoresistance remains a persistent challenge in advanced prostate cancer therapy. Probenecid reportedly inhibits multiple drug-efflux transporters; hence, it can be employed as a potential sensitizer for chemotherapy. In the present study, we evaluated the effects of probenecid on three-dimensional (3D)-cultures of prostate cancer cells. Main methods: Prostate cancer cell lines, 22Rv1 and PC-3 were cultured as multicellular tumor spheroids. The effects of probenecid were evaluated using the MTT assay for viability, microscopy for spheroid size, and soft agar colony formation assay for anchorage-independent growth. Key findings: The 3D-cultured 22Rv1 cells were less sensitive to cisplatin and doxorubicin than two-dimensional (2D) cell culture. Co-administration of probenecid at a low (100 or 300 μM), but not high (500 μM), concentration increased the sensitivity to cisplatin or doxorubicin in 22Rv1 spheroids. Probenecid increased the expression of ABCG2, a multidrug resistance transporter, in a dose-dependent manner. Furthermore, treatment with probenecid alone reduced the growth of 22Rv1 spheroids. Conversely, probenecid inhibited spheroid compaction rather than growth inhibition in 3D-cultured PC-3 cells. Moreover, probenecid inhibited colony formation of 22Rv1 and PC-3 cells in soft agar, as well as downregulated focal adhesion kinase (FAK), a crucial factor in anchorage-independent growth. Significance: In 3D-cultured prostate cancer cells, probenecid demonstrated pleiotropic effects such as chemosensitization, growth suppression, inhibition of spheroid compaction, and suppression of anchorage-independent growth. Elucidating the detailed mechanism underlying these probenecid actions could result in the identification of novel therapeutic targets toward the advanced prostate cancer.

    DOI: 10.1016/j.lfs.2021.119554

    Scopus

    PubMed

全件表示 >>

講演・口頭発表等 【 表示 / 非表示

  • 膀胱膣瘻及び尿管膣漏に対しPure Laparoscopic surgeryで修復術を行った一例

    膀胱膣瘻及び尿管膣漏に対しPure Laparoscopic surgeryで修復術を行った一例

    第36回日本内視鏡外科学会  2023年12月8日 

     詳細を見る

    開催年月日: 2023年12月7日 - 2023年12月9日

    会議種別:口頭発表(一般)  

  • 術前化学療法が奏功したリンパ節転移を 伴う尿道扁平上皮癌の一例

    永井崇敬,月野浩昌,村嶋隆哉,三宅那央,藤井将人,武田将司,佐藤俊介,山崎浩司, 上別府豊治,上村敏雄,向井尚一郎,賀本敏行

    第 68 回西日本泌尿器科学会総会 

     詳細を見る

    開催年月日: 2016年11月26日

    記述言語:日本語   会議種別:口頭発表(一般)  

  • 尿路上皮癌に対して GN(gemcitabine+nedaplatine)療法を行った 6 例.

    永井崇敬,山崎浩司,藤井将人,武田将司,佐藤俊介,月野浩昌,向井尚一郎,上村敏雄, 賀本敏行

    第 54回日本癌治療学会学術集会 

     詳細を見る

    開催年月日: 2016年10月21日

    記述言語:日本語   会議種別:口頭発表(一般)  

  • 膀胱粘膜下腫瘍の 2 例

    永井崇敬,秋山裕,三宅那央,藤井将人,武田将司,佐藤俊介,山崎浩司,上別府豊治, 月野浩昌,上村敏雄,向井尚一郎,賀本敏行:

    第 130 回日本泌尿器科学会鹿児島地方会, 

     詳細を見る

    開催年月日: 2016年7月9日

    記述言語:日本語   会議種別:口頭発表(一般)  

科研費(文科省・学振・厚労省)獲得実績 【 表示 / 非表示

  • 転移性CRPCにおける、HGF/METパスウェイを標的とした新規治療法の開発

    研究課題/領域番号:23K08737  2023年04月 - 2026年03月

    独立行政法人日本学術振興会  科学研究費基金  基盤研究(C)

     詳細を見る

    担当区分:研究分担者 

 

授業 【 表示 / 非表示

  • 生命と病気